Shares of GeneDx Holdings (WGS) dropped 8% to $62.43 in after-hours trading after the rare-disease genetic testing company delivered a Q2 that split cleanly down the middle: strong demand, weak bottom line, and no new promises for the year ahead. The selloff raises a pointed question about whether Wall Street has already priced in the growth story and now demands proof of profit.
Record Testing Volume Isn't Translating Into Proportional Revenue
GeneDx delivered $114.4 million in Q2 revenue and a record 30,785 exome and genome tests, up 32% year over year. Yet exome and genome revenue rose only 17% to $100.3 million — the gap reflecting an intentional shift toward whole genome testing, which currently carries lower average reimbursement rates.
Commercial coverage now reaches 87% of lives for genome testing and 98% for exome testing, but genome collection rates held at just 32%. In plain terms, insurers agree to pay for the tests but GeneDx is only collecting about a third of what it bills — a revenue leak the company says it cannot meaningfully fix until Q4 and into 2027.
Adjusted Profit Arrived Early, but GAAP Losses Actually Widened
The company achieved adjusted net income of $0.4 million, returning to profitability one quarter earlier than projected. However, on a GAAP basis GeneDx posted an operating loss of $17.5 million and a net loss of $17.7 million, or -$0.60 per diluted share.
That swung from net income of $10.81 million in the year-ago quarter.
Cash flow remained negative, with $29 million in operating cash burn. The divergence between the adjusted and GAAP numbers is exactly what spooked investors.
Unchanged Guidance Signals Caution After a Prior Cut
GeneDx reaffirmed full-year 2026 revenue of $475–$490 million and guided Q3 to $122–$124 million — below the $126 million consensus.
The company had already lowered its full-year outlook in May, so merely reaffirming the reduced target, rather than raising it after a beat, disappointed bulls.
Analysts Still See Upside, but Patience Is the Price of Admission
Multiple firms, including Canaccord and Piper Sandler, reiterated Buy ratings and boosted price targets to $90. Their thesis hinges on collection-rate improvements and newborn screening expansion — catalysts management itself says are mostly a 2027 story. For now, shareholders are paying a growth-stock price for a company still burning cash and asking them to wait.